期刊文献+

呼吸病区下呼吸道革兰阴性杆菌连续5年耐药性监测 被引量:6

Surveillance of antimicrobial resistance in gram-negative bacilli isolated from lower respiratory tract of patients in respiratory wards for 5 consecutive years
暂未订购
导出
摘要 目的探讨本所呼吸病区患者下呼吸道分离革兰阴性杆菌的耐药变迁,指导临床合理使用抗菌药物。方法2003—2007年从呼吸病区患者下呼吸道分离的非重复的1 709株革兰阴性杆菌,采用Kirby-Bauer法进行药敏试验,数据分析采用WHONET5.4软件。结果最常见的病原菌为铜绿假单胞菌(43.7%)、肺炎克雷伯菌(11.1%)、嗜麦芽窄食单胞菌(9.2%)和鲍曼不动杆菌(9.0%)。铜绿假单胞菌对头孢哌酮-舒巴坦的耐药率最低,其次是阿米卡星(10.1%~27.7%)和美罗培南(17.3%~31.8%)。嗜麦芽窄食单胞菌对头孢哌酮-舒巴坦(5.9%~17.9%)和左氧氟沙星(7.1%~17.4%)的耐药率较低。亚胺培南和美罗培南对鲍曼不动杆菌保持较强的抗菌活性,头孢哌酮-舒巴坦对该菌的耐药率(0~22.2%)明显低于替卡西林-克拉维酸(17.4%~50.0%)和哌拉西林-他唑巴坦(16.7%~61.5%)。肠杆菌科细菌对亚胺培南和美罗培南仍高度敏感,对氟喹诺酮类药物的耐药率较高,且各品种间呈交叉耐药。肺炎克雷伯菌对头孢吡肟(0~32.6%)和头孢哌酮-舒巴坦(2.4%~38.1%)的耐药率明显低于第三代头孢菌素(11.9%~69.0%)。肺炎克雷伯菌产ESBLs株检出率由2003年的16.1%上升至2005年的76.7%,2007年降至28.6%,而大肠埃希菌产ESBLs株检出率则由2003年的45.5%上升至2007年的80.6%。产ESBLs菌株对大多数β内酰胺类抗生素高度耐药。结论细菌耐药率明显升高,加强耐药性监测,合理使用抗菌药物非常重要。 Objective To investigate the change pattern of antimicrobial resistance among gram-negative bacilli isolated from lower respiratory tract for rational antibiotic therapy in clinical practice. Methods Antimicrobial susceptibility of 1 709 isolates of gram-negative bacilli from 2003 to 2007 was tested by disk diffusion (K-B) method. Whonet 5.4 software was used to analyze the data. Results The most common pathogens were Pseudomonas aeruginosa (43.7%), Klebsiella pneumoniae (11. 1%), Stenotrophomonas maltophilia (9.2 %) and Acinetobacter baumannii (9.0%). Resistance rate of P. aeruginosa was relatively lower to cefoperazone-sulbactam, amikacin (10.1%-27.7%) and meropenem (17.3% -31.8%). Resistance rate of S. maltophilia was relatively lower to cefoperazone-sulbactam (5.9%-17.9%) and levofloxacin (7.1%-17.4%). Most of A. baumannil isolates were susceptible to imipenem and meropenem. Resistance rate of A. baumannii isolates to cefoperazone-sulbactam (0-22.2%) was lower than ticarcillin-clavulanic acid (17.4%-50.0%) and piperacillin- tazobactam (16.7%-61.5%). Isolates of Enterobacteriaceae were still highly sensitive to imipenem and meropenem, but highly resistant to fluoroquinolones. Resistance rate of K. pneumoniae was lower to cefepime (0- 32.6 %) and cefoperazone-sulbactam (2.4 %-38.1 % ) than the third generation cephalosporins (11.9%-69.0%). The prevalence of extended-spectrum β-1actamases (ESBLs) in K. pneumoniae increased from 16.1% in 2003 to 76.7% in 2005, but decreased to 28.6% in 2007, while in Escherichia coli the prevalence increased from 45.5% in 2003 to 80.6% in 2007. ESBLs-produeing strains were resistant to most β-lactams and some other antimicrobial agents. Conclusions Most pathogens show significant resistance to the most commonly used antibiotics. It is very important to select antibiotics for the treatment of infections based on the results of susceptibility testing in respiratory wards.
出处 《中国感染与化疗杂志》 CAS 2009年第2期129-133,共5页 Chinese Journal of Infection and Chemotherapy
关键词 革兰阴性杆菌 耐药监测 耐药性 gram-negative bacterium resistance surveil- lance drug resistance
  • 相关文献

参考文献15

  • 1Clinical and Laboratory Standards Institute (CLSI). Preformance Standards for Antimicrobial Susceptibility tasting[S]. Seventeenth Informational Supplement M100-S16,2007.
  • 2汪复.2006年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2008,8(1):1-9. 被引量:283
  • 3Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004[J]. J Clin Microbiol, 2007,45 (10) :3352-3359.
  • 4朱德妹,张婴元,汪复.2006年上海地区细菌耐药性监测[J].中国感染与化疗杂志,2007,7(6):393-399. 被引量:100
  • 5Karlowsky JA,Jones ME,Thornsberry C,et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies[J]. Clin Infect Dis, 2005,40( Suppl 2) :S89-S98.
  • 6Paterson DL. The epidemiological profile of infections with muhidrug resistant Pseudomonas aeruginosa and Acinetobacter speeies[J]. Clin Infect Dis, 2006,43 ( Suppl 2) : S43-S48.
  • 7杨启文,王辉,徐英春,谢秀丽,孙宏莉,陈民钧.3种常见非发酵革兰阴性杆菌的体外药物敏感性[J].中国感染与化疗杂志,2007,7(3):198-201. 被引量:14
  • 8Rolston KV, Kontoyiannis DP, Yadegarynia D, et al. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones[J]. Diagn Microbiol Infect Dis,2005,51 (3) :215-218.
  • 9Tatman-Otkun M, Gurcan S, Ozer B, et al. The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness[J]. BMC Microbiol,2005,5(9):24-29.
  • 10王辉,孙宏莉,宁永忠,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.不动杆菌属多重耐药及泛耐药的分子机制研究[J].中华医学杂志,2006,86(1):17-22. 被引量:183

二级参考文献78

共引文献678

同被引文献40

  • 1林东昉,吴菊芳,张婴元,郑经川,缪竞智,郑丽叶,盛瑞媛,周新,沈华浩,吴卫红,周乐,汪复.利奈唑胺与万古霉素治疗革兰阳性菌感染的随机、双盲、对照、多中心临床试验[J].中国感染与化疗杂志,2009,9(1):10-17. 被引量:57
  • 2段宪武,郭伟,谢宝元.支气管肺泡灌洗液和气管内吸引物培养在迟发呼吸机相关肺炎患者中的比较研究[J].中国全科医学,2009,12(11):955-957. 被引量:3
  • 3张樱,陈亚岗,杨青.不动杆菌感染及耐药机制的研究进展[J].国外医学(流行病学.传染病学分册),2005,32(2):109-112. 被引量:93
  • 4National Nosooomial Infections Saveillance System.National Nosoeornial Infections Surveillance(NNIS)System Report,data summary from January 1992 through June 2004,issued October 2004[J].Am J Infect Control,2004,32(8):470-485.
  • 5Ribera A, Domenech SA, Ruiz J, et al. Mutation in gyrA and parC QRDRs are not relavant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates[J]. Microb Drug Resist, 2002,8(4):245-251.
  • 6Valdezate S, Vindel A, Saez-znieto JA, et al. Preservation of topoisomcrase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxaein in iogenic Stenotrophomonas maltophilia straim [J]. J Antimicrob Chemother, 2005,56(1):220-222.
  • 7Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of muhidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy[J]. Antimierob Agents Chemother, 2001,45(1):105-116.
  • 8Paterson DL.The epidemiological profile of infections with multidrug-resistant pseudomonas aeruginosa and acinetobacter species[J].Clin Infect Dis,2006,43:S43-S48.
  • 9Sader HS,Fritsche TR,Jones RN.Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers:results from the SENTRY Antimicrobial Surveillance Program (1998-2003)[J].Diagn Microbiol Infect Dis,2005,52(3):265-273.
  • 10Bell JM,Chitsaz M,Turnidge JD,et al.Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae:results from the SENTRY asia-Pacific surveillance program[J].J Clin Microbiol,2007,45(5):1478-1482.

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部